While the pharmaceutical market experiences the fervor for GLP-1 analogs, such as semaglutide, science seeks alternatives that operate outside the simplified axis of gastric satiety. Researchers at the University of Oklahoma in the United States have published promising results regarding the FGF21 hormone (Fibroblast Growth Factor 21), a substance that demonstrated the capacity to reverse obesity in laboratory tests.
The significant distinction lies in its mechanism of action. While currently popular medications simulate intestinal hormones to delay gastric emptying and reduce appetite, FGF21 acts more directly on energy balance and insulin sensitivity. This discovery suggests that lipid accumulation can be treated through a distinct, potentially more comprehensive, metabolic pathway.
Although tests are currently restricted to animal models, this advancement signals a new phase in metabolic medicine. Should these results translate to humans with comparable efficacy, FGF21 could not only complement the current therapeutic arsenal but also offer a viable alternative for patients who cannot tolerate the severe gastrointestinal side effects of existing treatments.
With information from Exame Inovação.
Source · Exame Inovação
